CT, RECIST, and malignant pleural mesothelioma.
The unique growth pattern of malignant pleural mesothelioma (MPM) presents challenges for clinical investigators assessing tumour response to treatment. Assessment of response is an important surrogate for patient benefit, particularly in phase II clinical trials. Neither the previous WHO criteria nor the more recent RECIST criteria are well suited to tumour measurement in this disease. This paper discusses uni-dimensional measurement of tumour response in pleural mesothelioma, and the development and validation of the modified RECIST criteria for MPM, which attempt to overcome some of the shortcomings of the RECIST criteria in this setting.
Nowak
Anna K
AK
Department of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009 Australia. anowak@cyllene.uwa.edu.au
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001837:Body Weights and Measures; D002986:Clinical Trials as Topic; D006801:Humans; D008654:Mesothelioma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D010997:Pleural Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D012074:Remission Induction; D014057:Tomography, X-Ray Computed; D047368:Tumor Burden
D000970:Antineoplastic Agents